The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886)...

European Journal of Cancer 2016 / 12 Vol. 69

The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Diallo, B., Massonnet, G., El-Botty, R., Raymondie, C., Howes, C., Wilson, J., Smith, A., Roman-Roman, S., Smith, P., Davies, E., Decaudin, D., Némati, F.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
69
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)32991-4
Date:
December, 2016
File:
PDF, 51 KB
english, 2016
Conversion to is in progress
Conversion to is failed